HIF1A and Alzheimer disease: Pharmacological inhibition of HIF-1α by a novel small molecular inhibitor KC7F2 could ameliorate IH exposure induced deleterious effects in our OSAS-AD mouse model, which potentiates its clinical application for AD patients with OSAS in the future (Figure 6).